In people with relapsing forms of multiple sclerosis (MS), relapses that occur in the first few years after the…
Articles by Marisa Wexler, MS
Pro-inflammatory immune cells that can target the brain may be activated in a specific region of the intestine by certain…
Octave Bioscience has raised $30 million in financing to help accelerate commercialization efforts for its precision care program for…
A new artificial intelligence (AI) algorithm could help identify people at risk of developing multiple sclerosis (MS). “Our model’s…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that PB006,…
In multiple sclerosis (MS), inflammation leads to less energy production in nerve fibers by reducing the levels of enzymes…
Synaptogenix is teaming up with Cleveland Clinic for a Phase 1 clinical trial involving people with multiple sclerosis…
A first-of-its-kind study is aiming to determine whether older adults with multiple sclerosis (MS) can safely stop taking…
With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple…
Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased…
A new formulation of Ocrevus (ocrelizumab), given as a 10-minute under-the-skin injection, was comparable to the approved intravenous version…
Inflammation in the membranes around the brain may trigger an inflammatory response that can spread into nearby brain tissue, a…
The biopharmaceutical company Imcyse has signed on to a new project that aims to use artificial intelligence (AI) to…
Treatment with estriol, a hormone that’s produced during pregnancy, reduced disease severity and promoted myelin repair in the cortex —…
The PoNS device — officially the Portable Neuromodulation Stimulator, designed to help improve walking ability in people with…
Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting…
It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field…
The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially…
For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but…
Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of…
People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after…
Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability…
Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with…
Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new…
The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis…
The average rate of relapses for multiple sclerosis (MS) in the modern era is lower than it has been…
Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in…
Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability…
An updated snapshot of multiple sclerosis (MS) in the U.S. — provided by new population estimates from a study…
When the immune system launches an attack to fight off infection with the Epstein-Barr virus, immune cells can accidentally…